Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) CEO Dr Eric Leire had the chance to sit down with Stephen Gunnion of Proactive to discusss the company’s recent successes and plans for the future. 🎥 Watch it here: https://lnkd.in/ewNqPr6U

🚀 Genflow Biosciences (LON:GENF) (OTCQB:GENFF) CEO Dr Eric Leire recently sat down with Zacks Small Cap Research to highlight Genflow’s strong year and exciting upcoming catalysts in longevity research. Don't miss his insights - watch the full conversation here: https://loom.ly/5x10V58 #GENF #GENFF #SIRT6 #aging #biotech

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is glad to announce that it has received official confirmation of €4,026,525 in non-dilutive financial support from the Wallonia region to support its MASH research. The funds are expected to cover three years of Genflow's development program for GF-1002, with the first installment being received as working capital. Read the release here: https://loom.ly/awLvA4A #GENF #GENFF #biotech #SIRT6 #MASH

🧬 New presentation alert! 🧬 Genflow Biosciences (LON:GENF) (OTCQB:GENFF) has just released a fresh presentation on its website, showcasing the latest in #SIRT6 research. Check it out here: https://loom.ly/qLRb1jE #biotech #smallcap #GENF #GENFF

🧬 Can Travel Slow Down Aging? 🧬 🌍 At Genflow Biosciences (LON:GENF) (OTCQB:GENFF), we’re always exploring cutting edge research that dives into the science of aging, and a recent study caught our attention! ✈️ A team from Edith Cowan University suggests that travel could potentially slow the aging process. 🧠 Travel offers: 🌳 Reduced stress & improved well being through exposure to new environments 👥 Boosted cognitive function by interacting with different cultures & people 💪 Physical activity involved in exploring new places ✨ Whether it’s an international adventure or a weekend getaway, the key is to embrace new experiences. Aging doesn’t have to slow you down, and at #Genflow, we’re focused on helping you live a longer, healthier, and more vibrant life. Read more about the study: https://loom.ly/hOxZ_Ww #Aging #Longevity #SIRT6 #GENF #GENFF

A recent study of over 95,000 athletes has uncovered fascinating links between specific sports and #lifespan. Some, like pole vaulting and #gymnastics, were correlated with significant increases while others, such as sumo wrestling, were negatively associated. Researches found that #sports mixing aerobic & anaerobic exercise saw the largest jumps. #Longevity research is crucial as we look to combat the growing costs of an aging population. At Genflow Biosciences (LON:GENF) (OTCQB:GENFF), we're working on #SIRT6 research that could revolutionize how we treat aging. Learn more about the study: https://loom.ly/okVciA8 #GENF #GENFF #aging #genetherapy #biotech

This just in - dogs are expensive! While this may be no surprise to many owners, a new MarketWatch article notes the cost of owning a dog can exceed $50,000 over its lifetime. With the pet care industry expected to surpass half a trillion USD by decade's end, much of that spending will be on veterinary care. This opens a major opportunity for dog anti-aging treatments in the near future. As Genflow Biosciences (LON:GENF) (OTCQB:GENFF) advances its #SIRT6 research, we aim to help extend the precious time we spend with our (expensive) furry best friends. Check out the full MarketWatch article here: https://loom.ly/AIQWe8U #dog #longevity #veterinarycare #GENF #GENFF

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)  announced significant progress in its primary longevity programmes and bolstered its financial position during the first half of 2024, according to the company's half-year results statement. The London-listed biotechnology firm has been making strides in developing treatments for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Werner Syndrome, both of which are age-related diseases with substantial unmet medical needs. In June, Genflow submitted a comprehensive briefing package to the US Food and Drug Administration for its lead drug candidate, GF-1002, aimed at treating MASH. The company anticipates receiving guidance through the FDA's Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) programme. While awaiting feedback, the FDA has encouraged Genflow to proceed with pilot proof-of-concept studies to identify suitable models. More at #Proactive #ProactiveInvestors http://ow.ly/3jiL105Konu

🔬 Groundbreaking discovery! 🔬 🦈 A team of scientists has mapped the genome of the Greenland shark, the world’s longest-living vertebrate! 🧬 Its unique DNA repair & unique gene functions may explain its longevity, while also contributing to #aging research that could benefit humans too! #GENF #GENFF #Longevity #Biotech #Genomics

🧬 Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is please to announce the release of our interim H1 2024 financial results! 🧬 “We remain focused on our mission to improve healthspan, and I look forward to providing you with further updates as we progress through our work programs, including clinical dog trials,” said #Genflow Chairman, Tamara Joseph. 👀 Read the report here: https://loom.ly/PRlZPQk #smallcap #biotech #aging #GENF #GENFF